Enhancing the hepatitis B care cascade in Australia: A cost‐effectiveness model

• DOI: 10.1111/jvh.13252
• Publication Date: 2019-12-19T17:46:49Z
• Authors: Yinzong Xiao; Jessica Howell; Caroline van Gemert; Alexander J. Thom...; Christopher P. Se...; Karen McCulloch; Nick Scott; Margaret E. Hellard
• Keywords: Hepatitis B

Abstract If Australia is to successfully eliminate hepatitis B as a public health threat, it will need enhance the chronic (CHB) care cascade. This study used Markov model assess impact, cost and cost‐effectiveness of scaling up CHB diagnosis, linkage treatment reach national international elimination targets for in Australia. Compared continued current trends, calculated difference cascade projection, disability‐adjusted life years (DALYs), costs incremental ratio (ICER), reach: (a) Australia's 2022 (b) WHO’s 2030 global targets. Achieving WHO had ICERs A$13 435 (A$10 236‐A$21 165) A$14 482 (A$13 031‐A$25 641) per DALY averted between 2016 Australia, respectively. However, this excluded implementation demand generation costs. The ICER National Strategy remained under A$50 000 if spent A$328 or A$538 million, respectively, annum (for 2016‐2030) on activities. Sensitivity analysis showed that was predominately driven by influenced disease progression rates. Hence Hepatitis targets, requires an improvement We estimated cost‐effective spend million year